Brokerages Set Repligen Corporation (NASDAQ:RGEN) Target Price at $166.43

Repligen Corporation (NASDAQ:RGEN) has earned an average recommendation of “Moderate Buy” from the eighteen ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, twelve have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $166.4286.

RGEN has been the subject of a number of recent research reports. Rothschild & Co Redburn set a $160.00 target price on Repligen and gave the stock a “buy” rating in a research report on Friday, April 17th. Evercore reissued an “outperform” rating and set a $160.00 price target on shares of Repligen in a research report on Monday, July 6th. Weiss Ratings upgraded shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, July 14th. Royal Bank Of Canada assumed coverage on shares of Repligen in a research note on Thursday, May 14th. They set an “outperform” rating and a $160.00 price objective for the company. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $142.00 target price on shares of Repligen in a report on Tuesday, May 5th.

Insider Buying and Selling

In other Repligen news, CFO Jason K. Garland sold 733 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the sale, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.60% of the stock is owned by insiders.

Institutional Trading of Repligen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Measured Wealth Private Client Group LLC bought a new position in Repligen in the 3rd quarter worth $29,000. Bayforest Capital Ltd bought a new stake in shares of Repligen during the 4th quarter valued at about $32,000. Rachor Investment Advisory Services LLC bought a new stake in shares of Repligen during the 4th quarter valued at about $33,000. Los Angeles Capital Management LLC purchased a new position in shares of Repligen during the fourth quarter valued at about $36,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new position in shares of Repligen during the second quarter valued at about $52,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $165.70 on Monday. The firm has a market capitalization of $9.35 billion, a PE ratio of 226.99, a P/E/G ratio of 3.00 and a beta of 1.03. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The company has a 50-day moving average price of $140.99 and a two-hundred day moving average price of $131.04. Repligen has a twelve month low of $100.99 and a twelve month high of $175.77.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business had revenue of $204.13 million for the quarter, compared to analysts’ expectations of $201.59 million. During the same quarter in the previous year, the firm posted $0.26 EPS. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities analysts forecast that Repligen will post 2.06 EPS for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.